Inflammatory Response Conventional Total Knee Replacement Versus Mako Total Knee Replacement
A Prospective Randomised Controlled Trial Comparing the Biochemical, Thermal, and Macroscopic Soft Tissue Outcomes in Conventional Jig-based Total Knee Arthroplasty Versus Mako Robotic-arm Assisted Total Knee Arthroplasty
1 other identifier
interventional
30
1 country
1
Brief Summary
Total knee Arthroplasty (TKA) is a highly effective treatment for knee osteoarthritis. Mid- to long-term follow-up studies have shown good clinical outcomes following TKA; despite these results, there is a high incidence of patient dissatisfaction; 20% of patients reporting dissatisfaction in otherwise uncomplicated procedures. One reason for early dissatisfaction may be the trauma of surgery may lead to localised and systemic inflammatory responses that impair postoperative clinical recovery; this in turn influences long-term functional outcomes. Surgical techniques that limit the insult of surgery and help to restore the patient's native knee anatomy and kinematics may help to improve clinical outcomes, functional recovery, and patient satisfaction. The technical objectives of surgery are to restore limb alignment, preserve the joint line, balance flexion and extension gaps, and maintain the normal Q angle for optimal patella tracking. Compromise to the periarticular soft tissue structures may compromise postoperative clinical and functional recovery, reduce stability, and decrease implant survivorship. In conventional jig-based (CO) TKA, bone cuts are most commonly performed using measured resection or gap balancing. The manual error associated with inadvertent soft tissue release during preparation for implantation or tissue damage from the saw blades is an accepted part of the procedure. The evolution of surgical technology has led to the development of robotic-arm assisted TKA, which uses three dimensional images of the patient's native knee anatomy to guide bone resection and optimise implant positioning. The second-generation RIO Robotic Arm Interactive Orthopaedic system (Mako surgical) uses preoperative computerised tomography scans to build a computer-aided design (CAD) model of the patient's knee joint. The Mako robotic software processes this information to calculate the volume of bone requiring resection and creates a three-dimensional haptic window for the RIO robotic arm to resect. In short, the robotic technology in TKA allows execution of the preoperative surgical plan without undue soft tissue release, inadvertent trauma from power tools, and minimal trauma to bone surfaces. Conceptually, this Mako TKA should have reduced soft tissue trauma and inflammatory response as assessed with inflammatory cytokines compared to CO TKA. The overall aim of this single centre, prospective randomised controlled trial is to determine differences in the inflammatory response between CO TKA and Mako TKA. A comprehensive range of local and systemic biochemical markers, thermal response, and macroscopic soft tissue injury outcomes between the two groups will be recorded and correlated to clinical and functional outcomes over 2-year postoperative. Patients undergoing CO TKA will form the control group and those undergoing Mako TKA will form the investigation group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable knee-osteoarthritis
Started Nov 2018
Longer than P75 for not_applicable knee-osteoarthritis
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 5, 2018
CompletedFirst Submitted
Initial submission to the registry
December 6, 2019
CompletedFirst Posted
Study publicly available on registry
December 10, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2022
CompletedJune 28, 2023
June 1, 2023
3.2 years
December 6, 2019
June 27, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum CRP level
Serum CRP level
48 hours post-op
Secondary Outcomes (25)
C-reactive Protein (CRP)
6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA
Interleukin-1 beta (IL1 beta)
6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA
Interleukin-6 (IL6)
6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA
Tumour necrosis Factor alpha (TNFalpha),
6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA
Creatine Kinase (CK)
6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA
- +20 more secondary outcomes
Study Arms (2)
Conventional
ACTIVE COMPARATORJig-based procedure
Robotic arm-assist
EXPERIMENTALMako robotic-arm assist based procedure
Interventions
Surgical implantation of prosthetic knee using robotic-arm assist
Eligibility Criteria
You may qualify if:
- Patient has symptomatic knee osteoarthritis requiring primary TKA
- Patient and surgeon are in agreement that TKA is the most appropriate treatment
- Patient is fit for surgical intervention following review by surgeon and anaesthetist
- Patient is between 18-80 years of age at time of surgery
- Gender: male and female
- Patient must be capable of giving informed consent and agree to comply with the postoperative review program
- Patient must be a permanent resident in an area accessible to the study site
- Patient must have sufficient postoperative mobility to attend follow-up clinics and allow for radiographs to be taken
You may not qualify if:
- Patient is not suitable for routine primary TKA e.g. patient has ligament deficiency that requires a constrained prosthesis
- Patient has inflammatory arthritis e.g. Rheumatoid arthritis
- Patient has local or systemic autoimmune disease
- Past medical history of cancer or chronic illness
- Patient has symptomatic arthritis of the contralateral knee
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University College, Londonlead
- Stryker EU Operations BVcollaborator
Study Sites (1)
University College London Hospital NHS Foundation Trust
London, NW1 2PG, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Fares S Haddad
UCL Hospitals NHS Foundation Trust
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 6, 2019
First Posted
December 10, 2019
Study Start
November 5, 2018
Primary Completion
December 31, 2021
Study Completion
March 1, 2022
Last Updated
June 28, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will not share
No plan